Damora Therapeutics (DMRA) Change in Cash (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Change in Cash data on file, last reported at $275.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 11388.36% year-over-year to $275.3 million; the trailing twelve-month figure through Mar 2026 stood at $520.5 million (up 5803.55% YoY), and the FY2025 full-year result was $242.7 million, up 3581.2% from the prior year.
• Change in Cash for Q1 2026 stood at $275.3 million, up from $250.0 million in the prior quarter.
• Across five years, Change in Cash topped out at $275.3 million in Q1 2026 and bottomed at -$17.0 million in Q1 2022.
• The 5-year median for Change in Cash is -$2.1 million (2023), against an average of $27.6 million.
• The widest annual swing landed in 2024, when Change in Cash plunged 182650.0%; it then soared 11388.36% in 2026.
• A 5-year view of Change in Cash shows it stood at $2.9 million in 2022, then sank by 164.27% to -$1.9 million in 2023, then plunged by 160.61% to -$4.9 million in 2024, then jumped by 5165.56% to $250.0 million in 2025, then climbed by 10.11% to $275.3 million in 2026.
• The last three Change in Cash figures came in at $275.3 million (Q1 2026), $250.0 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.

Peer Comparison